Susquehanna raises its price target on Endo Pharmaceuticals (Nasdaq: ENDP) from $29 to $30. The firm maintains a Positive rating.
This article: 106 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE